Linerixibat - Generic Drug Details

What are the generic sources for linerixibat and what is the scope of freedom to operate?

Linerixibat is the generic ingredient in one branded drug marketed by Glaxosmithkline and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Linerixibat has forty-two patent family members in thirty-nine countries.

One supplier is listed for this compound.

Summary for linerixibat

International Patents:	42
US Patents:	1
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	7
Patent Applications:	184
DailyMed Link:	linerixibat at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for linerixibat

Constraining patent/regulatory exclusivity:

TREATMENT OF CHOLESTATIC PRURITUS ASSOCIATED WITH PRIMARY BILIARY CHOLANGITIS (PBC) IN ADULT PATIENTS

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for linerixibat

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
GlaxoSmithKline	Phase 3
GlaxoSmithKline	Phase 1

See all linerixibat clinical trials

Pharmacology for linerixibat

Drug Class	Ileal Bile Acid Transporter Inhibitor
Mechanism of Action	Ileal Bile Acid Transporter Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for linerixibat

A05AX	Other drugs for bile therapy
A05A	BILE THERAPY
A05	BILE AND LIVER THERAPY
A	Alimentary tract and metabolism

US Patents and Regulatory Information for linerixibat

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	LYNAVOY	linerixibat	TABLET;ORAL	220295-001	Mar 17, 2026		RX	Yes	Yes			Y	Y
Glaxosmithkline	LYNAVOY	linerixibat	TABLET;ORAL	220295-001	Mar 17, 2026		RX	Yes	Yes
Glaxosmithkline	LYNAVOY	linerixibat	TABLET;ORAL	220295-001	Mar 17, 2026		RX	Yes	Yes

International Patents for linerixibat

Country	Patent Number	Title	Estimated Expiration
Argentina	081337	DERIVADOS DE 1,4-BENZOTIAZEPINAS, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA PREPARACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE TRASTORNOS METABOLICOS
Australia	2011245393
Brazil	112012026767	composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
Canada	2795543	COMPOSES CHIMIQUES (CHEMICAL COMPOUNDS)

LINERIXIBAT: Market Dynamics and Financial Trajectory

Last updated: May 2, 2026

What is LINERIXIBAT’s market position?

LINERIXIBAT is a niche gastrointestinal (GI) asset with market formation driven by (1) payer coverage for chronic GI indications, (2) gastroenterology prescribing concentration, and (3) competitive intensity from established small-molecule and biologic GI franchises. Because LINERIXIBAT’s commercial footprint is not evidenced in the public patent and regulatory record provided in this task, no defensible market sizing, channel allocation, pricing claims, or uptake curve can be produced.

Which market dynamics shape adoption?

LINERIXIBAT’s adoption pattern is determined by the standard GI-commercial levers below, with payer and prescriber behavior typically responding to these observable drivers:

• Indication clarity and label breadth: Products with tightly defined responder populations and clear diagnostic pathways see faster payer uptake than broad, hard-to-measure symptom targets.
• Dosing and regimen simplicity: Once-daily or otherwise low-burden oral dosing generally improves persistence and reduces prior authorization friction versus multi-step regimens.
• Safety and discontinuation risk: In GI, adverse event profiles that increase discontinuations (particularly treatment-limiting events) compress net revenue by lowering long-term retention.
• Formulary placement and step edits: Early losses in preferred status force reliance on non-preferred channels, increasing discounting and expanding administrative costs.
• Competition within the care pathway: GI therapies often substitute within the same treatment line. Competitive entry changes real-world utilization even when the drug’s MOA remains differentiated.

These dynamics govern how quickly LINERIXIBAT can translate regulatory approval into paid prescriptions and net sales, but the underlying numeric indicators (pricing, uptake, reimbursement rates, payer coverage timelines) are not included in the provided material.

How does competition likely affect LINERIXIBAT’s financial trajectory?

Without verified competitor mappings for LINERIXIBAT’s specific indication, line of therapy, and geography, any direct competitive schedule and pricing pressure analysis would be non-actionable. In general terms, GI assets face one of two financial paths:

• Consolidation path: If LINERIXIBAT is positioned as a replacement for a standard-of-care within the same treatment line, revenue growth is constrained by cannibalization rather than net-expansion of the treated population.
• Adjacency path: If it expands the eligible population or improves outcomes across comorbid subgroups, revenue can grow faster, but payer restrictions may delay uptake until real-world evidence accumulates.

A defensible trajectory requires label-specific competitor lists, which are not present here.

What does a realistic revenue and margin path look like for GI niche assets?

A practical financial trajectory for a GI niche asset usually tracks these line items:

1. Gross-to-net compression
   • Rebates, patient assistance, and contracting intensity rise as formulary access lags.
2. Cost structure
   • High field-force and HEOR spend lowers near-term margins but can lift paid coverage in later periods.
3. Commercial scale-up
   • Marketing and access teams expand after initial uptake is demonstrated, which reduces per-unit overhead only after sales volume stabilizes.
4. Lifecycle pressure
   • If additional indications or line-of-therapy data are not secured, growth tends to flatten earlier than broader franchise assets.

For LINERIXIBAT, the numeric trajectory cannot be calculated without: net sales history, segmental data by geography, and disclosed expense lines.

What can be concluded about LINERIXIBAT’s cashflow and investment profile?

No credible investment and cashflow profile can be derived for LINERIXIBAT from the information supplied in this task. Cash burn, gross margin, SG&A ratio, and runway are determined by actual financial statements, which are not provided.

Market dynamics scorecard (evidence-based only)

Because no verified commercialization or financial metrics for LINERIXIBAT are available in the provided context, the only evidence-based “scorecard” is structural: which known levers matter for GI drugs. Assigning numeric scores would be speculative and is not produced.

Driver	Directional impact on LINERIXIBAT economics	Required proof not provided
Formulary access timeline	Faster access lifts early net sales and reduces discounts	Formulary placement data, claims, payer communications
Price and contracting	Higher net price lifts revenue per treated patient	Wholesale acquisition price and net-to-gross
Persistence	Better safety and tolerability increases LTV	Discontinuation/retention data
Competitive intensity	More substitutes compress price and volume	Competitor mapping by indication and geography
Evidence generation	Stronger RWE supports coverage and reduced PA	Outcomes datasets and payer dossiers

Key constraints on estimating LINERIXIBAT’s market outcome

The task does not include:

• regulatory approval dates by geography
• branded product identity and INN-to-trade mapping
• initial launch geography and distribution partners
• net price and discount rates
• prescription uptake curves (TRx, new starts, persistence)
• competitor set and treatment-line positioning
• financial statements or guidance

Under these conditions, no defensible market dynamics quantification or financial trajectory forecast can be produced.

Key Takeaways

• LINERIXIBAT’s financial trajectory in GI is governed by formulary access, net price, persistence, safety-related discontinuation, and competitive substitution within the treatment line.
• A market forecast or revenue path for LINERIXIBAT cannot be produced from the information provided in this task because commercialization and financial inputs (pricing, uptake, claims, and disclosed financials) are not present.
• Actionable due diligence for investors and R&D leaders requires verified label-specific market entry data and actual net sales or claims-based uptake metrics for the marketed product.

FAQs

1. What drives first-year revenue for a niche GI drug like LINERIXIBAT?
   Formulary access speed, prior authorization friction, and early prescriber adoption within gastroenterology practices.

2. Does safety profile typically affect GI drug profitability?
   Yes. Treatment-limiting adverse events increase discontinuation and reduce lifetime value, raising cost per retained patient.

3. How does competition shape net price outcomes in GI?
   Substitution within the same treatment line pushes payers to tighten restrictions and increases discounting through contracting.

4. What is the most reliable way to model GI adoption?
   Claims-based metrics (paid TRx, new starts, persistence) tied to formulary and PA status rather than early headline prescription counts.

5. What financial metrics matter most for estimating LINERIXIBAT’s trajectory?
   Net sales growth, gross-to-net compression, SG&A intensity, and retention/discontinuation rates.

---

References

[1] No source material was provided in the prompt text to cite for LINERIXIBAT’s market or financial metrics.